Search

everythinglearnresearchcommunity

for

Search:↓

Early diagnosis and treatment of frontal fibrosing alopecia are crucial to prevent permanent hair loss.

The document concludes that hair loss in women can be treated with topical treatments or hormone therapy depending on the cause.

UK medical students lack dermatology education, liver biopsy patients with risk factors show more fibrosis, and certain fungi resist drugs due to melanin; genetics may influence female hair loss.

Testosterone therapy can help with androgen deficiency in women but should be used with caution and monitoring due to potential risks.

Genetics, low estrogen, and low iron levels contribute to female hair loss, with specific scalp signs indicating severity.

Frontal fibrosing alopecia is a type of hair loss that usually happens after menopause.

A woman's skin darkened after using dutasteride and pimecrolimus for hair loss, but improved when she stopped the medications and protected her skin from light.

Menopause worsens skin, hair, and nails, affecting self-esteem and quality of life.

A woman's high testosterone and related symptoms were caused by overactive cells in her ovaries.

Combination of 0.25% finasteride and 3% minoxidil works better than just 3% minoxidil for increasing hair thickness in women.

Dermoscopy helps diagnose frontal fibrosing alopecia by distinguishing it from other hair loss conditions.

Treatments for Frontal Fibrosing Alopecia have not been proven effective.

Blood tests can detect ovarian Leydig cell tumors when scans don't, and surgery can confirm and treat these tumors.

The article concludes that understanding Frontal Fibrosing Alopecia (FFA) is crucial for effective treatment, which includes medication like 5α-reductase inhibitors and hydroxychloroquine.

Ovarian steroid cell tumors should be considered in adults with hirsutism and high testosterone, with surgery as the main treatment.

Upper eyelid hyperpigmentation can help diagnose facial lichen planus pigmentosus in patients with frontal fibrosing alopecia.

The document concludes that doctors should check for frontal fibrosing alopecia in patients with acquired hyperpigmentation and that early treatment is important.

A woman's hair loss was linked to a rare hormone-secreting ovarian tumor, treated with surgery and hair loss medication.

The study found that the average age of women diagnosed with Frontal Fibrosing Alopecia in Argentina is higher than in other countries, but their symptoms are similar.

High levels of male hormones in women without tumors are linked to metabolic problems and can be treated with metformin.

Maintaining sexual health after menopause is possible with patient approaches, hormone supplements, and therapy, despite needing more research.

A woman's pelvic pain and bleeding led to finding and successfully treating a rare benign tumor in her reproductive system.

A rare ovarian tumor caused hair loss in a post-menopausal woman, which almost completely stopped after surgery.

Hydroxychloroquine effectively reduces symptoms of frontal fibrosing alopecia, especially in the first 6 months.

The treatment helped reduce symptoms and stabilize the hairline in most patients with Frontal Fibrosing Alopecia, but hair regrowth was limited.

Combination therapy with steroids and pimecrolimus improved or stabilized hair loss in most patients with Frontal Fibrosing Alopecia, who also had a high rate of hypothyroidism.

Testosterone treatment can improve sexual function and bone density in women but may have adverse effects and requires more research on safety and guidelines.

Frontal Fibrosing Alopecia might be an autoimmune disease.

The cause of Frontal fibrosing alopecia, a type of hair loss, is complex, likely involving immune responses and genetics, but is not fully understood.

The study found that imaging might miss small ovarian tumors causing high testosterone, and suggested using certain testosterone levels and treatment responses to identify these tumors.